BR0110319A - Proteìnas depositadas sobre partìculas biocompatìveis, de baixa solubilidade para liberação controlada de proteìnas de uma matriz polimérica em um ambiente biológico - Google Patents

Proteìnas depositadas sobre partìculas biocompatìveis, de baixa solubilidade para liberação controlada de proteìnas de uma matriz polimérica em um ambiente biológico

Info

Publication number
BR0110319A
BR0110319A BR0110319-9A BR0110319A BR0110319A BR 0110319 A BR0110319 A BR 0110319A BR 0110319 A BR0110319 A BR 0110319A BR 0110319 A BR0110319 A BR 0110319A
Authority
BR
Brazil
Prior art keywords
proteins
protein
deposited
low solubility
particle
Prior art date
Application number
BR0110319-9A
Other languages
English (en)
Other versions
BRPI0110319B1 (pt
Inventor
Chung Shih
Gaylen Zentner
Ai-Zhi Piao
Original Assignee
Macromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macromed Inc filed Critical Macromed Inc
Publication of BR0110319A publication Critical patent/BR0110319A/pt
Publication of BRPI0110319B1 publication Critical patent/BRPI0110319B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

"PROTEìNAS DEPOSITADAS SOBRE PARTìCULAS BIOCOMPATìVEIS, DE BAIXA SOLUBILIDADE PARA LIBERAçãO CONTROLADA DE PROTEìNAS DE UMA MATRIZ POLIMéRICA EM UM AMBIENTE BIOLóGICO". A presente invenção refere-se a composições e processos para a liberação modulada de uma ou mais proteínas ou peptídeos. A composição é compreendida por uma matriz polimérica biocompatível, uma proteína e/ou peptídeo, e uma partícula de baixa solubilidade ou essencialmente insolúvel em água. A proteína é depositada por adsorção ou algum outro mecanismo sobre a partícula biocompatível de baixa solubilidade em água em que a combinação proteína-partícula é dispersa dentro da matriz polimérica. A deposição da proteína sobre a partícula atua no sentido de modular a liberação da proteína ou peptídeo de formas de dosagem incluindo sistemas de dosagens de ação prolongada.
BRPI0110319A 2000-04-07 2001-04-06 forma farmacêutica para liberação controlada de proteína em um meio biológico BRPI0110319B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19570000P 2000-04-07 2000-04-07
US09/827,100 US6998137B2 (en) 2000-04-07 2001-04-05 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
PCT/US2001/011217 WO2001076558A1 (en) 2000-04-07 2001-04-06 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix

Publications (2)

Publication Number Publication Date
BR0110319A true BR0110319A (pt) 2003-07-29
BRPI0110319B1 BRPI0110319B1 (pt) 2016-09-27

Family

ID=26891244

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0110319A BRPI0110319B1 (pt) 2000-04-07 2001-04-06 forma farmacêutica para liberação controlada de proteína em um meio biológico

Country Status (19)

Country Link
US (1) US6998137B2 (pt)
EP (1) EP1267838B1 (pt)
JP (2) JP4731088B2 (pt)
KR (1) KR100923817B1 (pt)
CN (1) CN100518814C (pt)
AT (1) ATE526947T1 (pt)
AU (1) AU2001251389A1 (pt)
BR (1) BRPI0110319B1 (pt)
CA (1) CA2405030C (pt)
CY (1) CY1112294T1 (pt)
DK (1) DK1267838T3 (pt)
ES (1) ES2374224T3 (pt)
HK (1) HK1057705A1 (pt)
IL (2) IL152131A0 (pt)
MX (1) MXPA02009790A (pt)
NZ (1) NZ521994A (pt)
PT (1) PT1267838E (pt)
WO (1) WO2001076558A1 (pt)
ZA (1) ZA200208039B (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
EP1273314A1 (en) * 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
AU2002321818A1 (en) * 2001-08-27 2003-03-10 Yissum Research Development Compagny Of The Hebrew University Of Jerusalem Multi-component polymeric systems with reverse thermal gelation behaviour (e.g. peo-ppo copolymers)
WO2003022242A1 (en) * 2001-09-11 2003-03-20 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1864681A1 (en) 2001-12-18 2007-12-12 Eidgenössische Technische Hochschule Zürich Growth factor modified protein matrices for tissue engineering
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
WO2004096179A1 (en) * 2003-05-01 2004-11-11 Ltt Bio-Pharma Co., Ltd. Zinc-containing sustained-release composition, its preparation, and method for producing the same
EP1719523A4 (en) * 2004-02-26 2009-07-15 Japan Science & Tech Agency MICROPARTICULAR PROTEIN CARBIDE RETARD PREPARATION FOR INJECTION AND METHOD FOR THE PRODUCTION THEREOF
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
KR100810736B1 (ko) * 2006-08-21 2008-03-07 광주과학기술원 다당류-기능화 나노입자 및 수화젤 담체를 포함하는복합체, 이를 포함하는 서방형 약물전달 제제, 뼈충진제 및이들의 제조방법
CA2621806C (en) 2005-09-14 2016-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2619455A1 (en) * 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7947368B2 (en) * 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
RU2413506C2 (ru) * 2006-08-11 2011-03-10 Панацея Биотек Лимитед Частицы для доставки активных ингредиентов, способ их получения и композиции из них
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009139924A2 (en) 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
EP2293784B1 (en) 2008-06-03 2016-04-13 Indivior UK Limited Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
KR100951554B1 (ko) 2008-06-04 2010-04-09 아주대학교산학협력단 마이셀 형성 및 약물 방출 제어가 가능한 6-팔ｐｌｌａ-ｐｅｇ 블록 공중합체
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
KR101367479B1 (ko) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US9718860B2 (en) * 2009-11-03 2017-08-01 Korea University Research And Business Foundation Complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, and use thereof
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
JP6224579B2 (ja) * 2011-04-11 2017-11-01 インデュース バイオロジクス インコーポレイテッドＩｎｄｕｃｅ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 増殖因子の多相放出を行うためのシステムおよび方法
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US9062151B1 (en) 2012-09-21 2015-06-23 The United States of America, as represented by The Secretary of Agiculture Protein-cyanoacrylate nanoparticles that improve wetting property of materials
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
KR101496153B1 (ko) * 2013-05-16 2015-02-27 오스템임플란트 주식회사 약물 담지 골형성 이식재 및 골 형성방법
WO2014190349A2 (en) * 2013-05-24 2014-11-27 Northeastern University Nanomaterials for the integration of soft into hard tissue
KR102321339B1 (ko) * 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
WO2015127315A1 (en) 2014-02-20 2015-08-27 Otitopic Inc. Dry powder formulations for inhalation
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US9895354B2 (en) 2014-04-04 2018-02-20 University Of Kentucky Research Foundation Bilayered calcium sulfate/calcium phosphate space-making composites with multiple drug delivery capabilities
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3179985A1 (en) * 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
KR102001289B1 (ko) 2016-10-13 2019-07-17 고려대학교 산학협력단 산화아연 결합 펩티드 서열, 이를 포함하는 복합체, 및 상기 복합체를 포함하는 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
EP0674506B1 (en) * 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
DK0779806T3 (da) * 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
ATE204468T1 (de) * 1995-06-07 2001-09-15 Alkermes Inc Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
DE69735384T2 (de) * 1996-12-20 2006-08-10 Alza Corp., Mountain View Gelzusammensetzungen und verfahren
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
KR100633939B1 (ko) * 1997-10-03 2006-10-16 마크로메드 인코퍼레이티드 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6711968B2 (en) 2002-08-02 2004-03-30 Visteon Global Technologies, Inc. Axle differential assembly

Also Published As

Publication number Publication date
KR100923817B1 (ko) 2009-10-27
ZA200208039B (en) 2004-02-04
HK1057705A1 (en) 2004-04-16
ES2374224T3 (es) 2012-02-14
NZ521994A (en) 2003-08-29
CA2405030A1 (en) 2001-10-18
IL152131A (en) 2010-11-30
CN100518814C (zh) 2009-07-29
WO2001076558A1 (en) 2001-10-18
JP4731088B2 (ja) 2011-07-20
EP1267838A1 (en) 2003-01-02
JP2011026336A (ja) 2011-02-10
CN1430504A (zh) 2003-07-16
BRPI0110319B1 (pt) 2016-09-27
DK1267838T3 (da) 2012-01-23
ATE526947T1 (de) 2011-10-15
PT1267838E (pt) 2012-01-11
JP2004507450A (ja) 2004-03-11
CA2405030C (en) 2011-01-25
AU2001251389A1 (en) 2001-10-23
US6998137B2 (en) 2006-02-14
MXPA02009790A (es) 2003-06-19
US20020015737A1 (en) 2002-02-07
CY1112294T1 (el) 2015-12-09
JP5193262B2 (ja) 2013-05-08
EP1267838B1 (en) 2011-10-05
IL152131A0 (en) 2003-05-29
EP1267838A4 (en) 2009-01-14
KR20030009425A (ko) 2003-01-29

Similar Documents

Publication Publication Date Title
BR0110319A (pt) Proteìnas depositadas sobre partìculas biocompatìveis, de baixa solubilidade para liberação controlada de proteìnas de uma matriz polimérica em um ambiente biológico
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
BR0214438A (pt) Composição farmacêutica para absorção nasal
JP2002535108A5 (pt)
BR0112532A (pt) Composição farmacêutica oral, sistema galênico e uso da composição
BR0208183A (pt) Peptìdeo modificado por wt1
BR9913343A (pt) Formulações de caseìna para a distribuição de constituintes bioativos
ATE437647T1 (de) Transporter mit beabstandeten arginin-teilchen
HUP0101250A2 (hu) Abszorbeálható mikrorészecskék
PT1137400E (pt) Composicoes contendo um peptideo e um acido polilactico-glicolico apropriado para preparar implantes subscutaneos com um periodo de libertacao prolongado
HRP20010463B1 (en) Controlled release galantamine composition
WO1997026864A3 (en) Methods and compositions for enhancing the bioadhesive properties of polymers
SV1999000096A (es) Calcio (3s) de propilcarbamato tetrahidro 3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonilo] (isobutilo) amino]-1-bencilo-2-+fosfonooxilo ref. pg3508/sv/0
DK0679097T3 (da) TGF-Beta-præparat til fremkaldelse af knoglevækst
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BR0109934A (pt) Preparação e prevenção de diarréia de ácido biliar
Imazato et al. Effects of monomers eluted from dental resin restoratives on osteoblast‐like cells
WO2005123034A3 (en) Microparticulate systems for the oral administration of biologically active substances
BR0316437A (pt) Composição cosmeticamente aceitável para tratamento da pele, e, método para tratar a pele
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
CA2124566A1 (en) Allosteric modulators of the nmda receptor
BR9810703A (pt) Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta
BR9814751A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, e, uso de um grande número de partìculas porosas inorgânicas que são compostas de hidroxiapatita de cerâmica.
BR0211245A (pt) Alimento contendo proteìna compreendendo uma enzima de ligação cruzada e um hidrocolóide
WO2001097785A3 (en) Basic copolymers for the treatment of prion-related-disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/14

Ipc: A61K 9/10 (2011.01), A61K 9/14 (2011.01), A61P 3/0

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: PETICAO NAO CONHECIDA NO 020100116636 ( RJ ) DE 14/12/2010

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/09/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI